Posted: Wednesday, January 19, 2022
Bin Fu, MD, PhD, of the First Affiliated Hospital of Nanchang University, China, and colleagues appear to have established and validated a prognostic signature comprising 11 genes involved in lipid metabolism, which may serve as an indicator for predicting the therapeutic effect of immunotherapy in patients with bladder cancer. A detailed report of the study was published in the journal Lipids in Health and Disease.
“Increasing evidence has confirmed that immune cell infiltration was strongly associated with the development, progression, and prognosis, as well as the treatment of bladder cancer,” said the authors. “The prognostic signature was an independent prognostic indicator, and [it] was correlated with immune cell infiltration.”
The authors acquired lipid metabolism–related genes from the Molecular Signature Database. The Cancer Genome Atlas and Gene Expression Omnibus data sets were used to obtain lipid metabolism–related gene mRNA expression and patient clinical data. The study investigated the prognosis, small-molecule drugs for treatment, and immunologic characters of patients with bladder cancer.
The study appears to have validated 11 lipid metabolism–related genes to predict the prognosis of patients with bladder cancer. Regulatory T-cell and dendritic cell activation seemed to be significantly elevated in the low-risk group compared with the high-risk group; regulatory T cells may promote tumor progression by suppressing effective antitumor immunity and reducing immunotherapy benefits. Patients in the high-risk group had higher expression of PD-1, CTLA-4, PD-L1, HAVCR2, and LAG-3 than those in the low-risk group, which may play a role in the unfavorable prognosis of this population. The authors identified five small-molecule drugs that may be candidates for the treatment of patients with bladder cancer.
Disclosure: The study authors reported no conflicts of interest.